시장보고서
상품코드
1429593

세계의 페그필그라스팀 바이오시밀러 시장 보고서(2024년)

Pegfilgrastim Biosimilars Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

페그필그라스팀 바이오시밀러 시장 규모는 향후 몇 년 동안 크게 성장할 것으로 예상됩니다. 2028년에는 7.4%의 연평균 복합 성장률(CAGR)로 23억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 암 발병률 증가, 고령화 인구 증가, 승인 건수 증가, 목표 및 인센티브의 존재 등의 요인에 기인합니다. 예측 기간 동안 주목할 만한 동향으로는 신규 및 강화된 바이오시밀러 개발에 대한 느슨한 규제 활용, 효과적이고 혁신적인 생물학적 제제를 개발하기 위한 R&D 노력에 대한 막대한 투자, 바이오시밀러 R&D 활동을 확대하기 위해 저명한 기업들과 파트너십을 맺는 전략적 초점 등이 있습니다. 신약 개발, 고객 기반과 지리적 시장을 확대하기 위한 인수합병(M&A)을 통한 성장 전략에 대한 관심이 높아지고 있습니다. 또한, 호중구감소증 치료용 바이오시밀러 생산에 대한 관심이 높아지면서 수익과 제품 공급을 강화하기 위해 바이오시밀러 생산에 대한 관심이 높아지고 있습니다.

바이오시밀러 개발 촉진을 위한 정부의 노력이 페그필그라스팀 바이오시밀러 시장을 견인할 것으로 예상됩니다. 전 세계 각국 정부는 바이오시밀러의 비용 효율성 때문에 바이오시밀러 개발에 우선순위를 두고 있습니다. 미국 식품의약국(FDA)의 바이오시밀러 행동계획(Biosimilar Action Plan)과 호주 정부의 바이오시밀러 교육 및 활동 지원을 위한 500만 달러의 보조금 지원을 통한 바이오시밀러 인식 제고 이니셔티브와 같은 노력은 바이오시밀러에 대한 인식과 생산을 강화합니다. 이러한 노력은 전체 페그필그라스팀 바이오시밀러 시장의 성장에 기여할 것입니다.

암의 유병률 증가는 페그필그라스팀 바이오시밀러 시장의 성장을 촉진하는 중요한 요인이 될 것으로 예상됩니다. 비정상적인 세포의 통제되지 않은 성장과 확산을 특징으로 하는 암의 새로운 사례가 증가하고 있습니다. 페그필그라스팀 바이오시밀러는 백혈구 생성을 자극하여 화학요법을 받는 암 환자의 감염 위험을 줄이는 데 중요한 역할을 합니다. 예를 들어, 2021년 미국 암 협회는 미국의 신규 암 환자 수가 2020년 180만 명에서 2021년 190만 명으로 증가했으며, 암 관련 사망자 수는 2020년 606,520명에서 2021년 608,570명으로 소폭 증가했다고 보고했습니다. 암 발생률 증가는 페그필그라스팀 바이오시밀러 시장의 주요 촉진요인입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 시장에 미치는 영향
  • COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모와 성장

  • 세계의 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계의 시장 규모 실적과 성장, 2018-2023년
  • 세계의 시장 규모 예측과 성장, 2023-2028년, 2033년

제6장 시장 세분화

  • 세계의 페그필그라스팀 바이오시밀러 시장, 용도별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 화학요법 치료
  • 이식
  • 기타 용도
  • 세계의 페그필그라스팀 바이오시밀러 시장, 유통 채널별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 병원 약국
  • 소매 약국
  • 통신 판매 약국

제7장 지역 및 국가 분석

  • 세계의 페그필그라스팀 바이오시밀러 시장, 지역별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 세계의 페그필그라스팀 바이오시밀러 시장, 국가별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 상황과 기업 개요

  • 페그필그라스팀 바이오시밀러 시장 경쟁 상황
  • 페그필그라스팀 바이오시밀러 시장 기업 개요
    • Coherus BioSciences
    • Sandoz
    • Biocon/Mylan
    • Intas Biopharmaceuticals Ltd
    • Mundipharma GmbH

제31장 기타 주요 및 혁신적인 기업

  • Dr. Reddy's Laboratories
  • Pfizer Inc.
  • Emcure Pharmaceuticals
  • USV Private Limited
  • Apotex Pty Ltd
  • Kyowa Kirin Co. Ltd
  • Qilu Pharmaceutical
  • Gennova Biopharmaceuticals Limited
  • Lupin Limited
  • Coherus Biosciences Inc
  • Fresenius Kabi
  • Napp Pharmaceuticals
  • Boicon
  • Amega Biotech.
  • Glenmark Pharmaceuticals Ltd

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병

제35장 향후 전망과 가능성 분석

제36장 부록

ksm 24.03.21

Pegfilgrastim biosimilars are biosimilar products designed to be used in conjunction with supportive care for individuals with non-myeloid cancer. These biosimilars aid in preventing or treating infections resulting from myelosuppressive chemotherapy by stimulating the production of specific white blood cells.

The diverse applications of pegfilgrastim biosimilars include their use in chemotherapy treatment, transplantation, and other medical scenarios. Chemotherapy is a cancer treatment method that involves the administration of one or more anti-cancer medications following a specified protocol. These biosimilars are made available through various distribution channels, including hospital pharmacies, retail pharmacies, and mail-order pharmacies.

The pegfilgrastim biosimilars market research report is one of a series of new reports from The Business Research Company that provides pegfilgrastim biosimilars market statistics, including pegfilgrastim biosimilars industry global market size, regional shares, competitors with a pegfilgrastim biosimilars market share, detailed pegfilgrastim biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the pegfilgrastim biosimilars industry. This pegfilgrastim biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pegfilgrastim biosimilars market size has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.75 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The expansion observed in the historical period can be ascribed to factors such as the rise in cancer prevalence, governmental initiatives, augmented healthcare expenditure, an upswing in biopharmaceutical research and development spending, the cost-effectiveness of biosimilars, and widespread adoption of biosimilar drugs.

The pegfilgrastim biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The anticipated growth in the forecast period can be attributed to factors such as the increasing prevalence of cancer, a growing aging population, a rising number of approvals, and the presence of targets and incentives. Noteworthy trends in the forecast period encompass leveraging less stringent regulations for the development of novel and enhanced biosimilars, substantial investments in research and development endeavors to create effective and innovative biologics, a strategic emphasis on establishing partnerships with prominent players to broaden research and development activities for new drug developments, and an increased focus on merger and acquisition growth strategies to expand the customer base and geographic markets. Additionally, there is a heightened focus on the production of biosimilars for the treatment of neutropenia to enhance revenues and product offerings.

Government initiatives aimed at promoting the development of biosimilars are anticipated to be a driving force behind the pegfilgrastim biosimilars market. Governments on a global scale are prioritizing biosimilar development due to its cost-effectiveness. Initiatives such as the Biosimilar Action Plan launched by the US Food and Drug Administration (FDA) to expand treatment options and the commitment of the Australian government to the Biosimilar Awareness Initiative through a $5 million grant to support biosimilar education and activities highlight the concerted efforts to enhance awareness and production of biosimilars. These endeavors contribute to the overall growth of the pegfilgrastim biosimilars market.

The increasing prevalence of cancer is expected to be a significant factor propelling the growth of the pegfilgrastim biosimilars market. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, has seen a rise in new cases. Pegfilgrastim biosimilars play a crucial role in reducing the risk of infection in cancer patients undergoing chemotherapy by stimulating white blood cell production. For example, in 2021, The American Cancer Society reported an increase in new cancer cases in the USA from 1.8 million in 2020 to 1.9 million in 2021, with a slight rise in cancer-related deaths from 606,520 in 2020 to 608,570 in 2021. Consequently, the growing incidence of cancer is a key driver for the pegfilgrastim biosimilars market.

Companies operating in the pegfilgrastim biosimilar market are enhancing their product innovation through strategic collaborations. To thrive in the increasingly competitive market, these companies are not only developing innovative products but also leveraging partnerships to share skills and expertise. While collaborations with academic and research institutions have been a common practice, this trend has gained momentum in recent years. For example, in May 2023, Amneal Pharmaceuticals, a US-based generics and specialty pharmaceutical company, joined forces with Kashiv Biosciences, a US-based integrated biosciences company, to collaboratively develop and introduce Fylnetra (pegfilgrastim-pbbk), a biosimilar pegfilgrastim. Fylnetra is a preservative-free, clear solution provided in a 6 mg/0.6 mL single-dose prefilled syringe, aiming to reduce infection risks, specifically febrile neutropenia, in patients with non-myeloid cancers undergoing certain myelosuppressive anti-cancer treatments.

Major companies in the pegfilgrastim biosimilars market are introducing high-quality products such as Stimufend to offer improved alternatives. Stimufend, launched by Fresenius Kabi, a Germany-based healthcare company, in February 2023, is a therapeutic drug designed to assist cancer patients in addressing neutropenia. Available as a 6 mg/0.6 mL solution in a single-use pre-filled syringe with a built-in needle guard, Stimufend marks the company's entry into the U.S. biosimilars market for cancer care, providing healthcare professionals with a high-quality treatment alternative.

In February 2022, Biocon Biologics Ltd., an India-based fully integrated biopharmaceutical company, completed the acquisition of Viatris' biosimilar business for $3.34 billion. This strategic move enables Biocon Biologics to direct-market more of its existing and upcoming biosimilars. As part of the acquisition, Viatris, a US-based pharmaceutical and healthcare corporation, is expected to provide commercial and other transition services to ensure a smooth transition and maintain customer service for an anticipated two-year term.

Major companies operating in the pegfilgrastim biosimilars market report are Coherus BioSciences, Sandoz, Biocon/Mylan, Intas Biopharmaceuticals Ltd., Mundipharma GmbH, Dr. Reddy's Laboratories, Pfizer Inc., Emcure Pharmaceuticals, USV Private Limited, Apotex Pty Ltd., Kyowa Kirin Co. Ltd., Qilu Pharmaceutical, Gennova Biopharmaceuticals Limited, Lupin Limited, Coherus Biosciences Inc., Fresenius Kabi, Napp Pharmaceuticals, Boicon, Amega Biotech.

North America was the largest region in the pegfilgrastim biosimilars market in 2023. The Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pegfilgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The pegfilgrastim biosimilars market consists of sales of fulphila, pelgraz, pelmeg, udenyca, ziextenzo, grasustek, fylnetra, and stimufend. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pegfilgrastim Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pegfilgrastim biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pegfilgrastim biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pegfilgrastim biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Application: Chemotherapy Treatment; Transplantation; Other Applications
  • 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Mail-Order Pharmacies
  • Companies Mentioned: Coherus BioSciences; Sandoz; Biocon/Mylan; Intas Biopharmaceuticals Ltd; Mundipharma GmbH
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pegfilgrastim Biosimilars Market Characteristics

3. Pegfilgrastim Biosimilars Market Trends And Strategies

4. Pegfilgrastim Biosimilars Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Pegfilgrastim Biosimilars Market Size and Growth

  • 5.1. Global Pegfilgrastim Biosimilars Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Pegfilgrastim Biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Pegfilgrastim Biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Pegfilgrastim Biosimilars Market Segmentation

  • 6.1. Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chemotherapy Treatment
  • Transplantation
  • Other Applications
  • 6.2. Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail-Order Pharmacies

7. Pegfilgrastim Biosimilars Market Regional And Country Analysis

  • 7.1. Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Pegfilgrastim Biosimilars Market

  • 8.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Pegfilgrastim Biosimilars Market

  • 9.1. China Pegfilgrastim Biosimilars Market Overview
  • 9.2. China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Pegfilgrastim Biosimilars Market

  • 10.1. India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Pegfilgrastim Biosimilars Market

  • 11.1. Japan Pegfilgrastim Biosimilars Market Overview
  • 11.2. Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Pegfilgrastim Biosimilars Market

  • 12.1. Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Pegfilgrastim Biosimilars Market

  • 13.1. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Pegfilgrastim Biosimilars Market

  • 14.1. South Korea Pegfilgrastim Biosimilars Market Overview
  • 14.2. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Pegfilgrastim Biosimilars Market

  • 15.1. Western Europe Pegfilgrastim Biosimilars Market Overview
  • 15.2. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Pegfilgrastim Biosimilars Market

  • 16.1. UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Pegfilgrastim Biosimilars Market

  • 17.1. Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Pegfilgrastim Biosimilars Market

  • 18.1. France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Pegfilgrastim Biosimilars Market

  • 19.1. Italy Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Pegfilgrastim Biosimilars Market

  • 20.1. Spain Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Pegfilgrastim Biosimilars Market

  • 21.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview
  • 21.2. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Pegfilgrastim Biosimilars Market

  • 22.1. Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Pegfilgrastim Biosimilars Market

  • 23.1. North America Pegfilgrastim Biosimilars Market Overview
  • 23.2. North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Pegfilgrastim Biosimilars Market

  • 24.1. USA Pegfilgrastim Biosimilars Market Overview
  • 24.2. USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Pegfilgrastim Biosimilars Market

  • 25.1. Canada Pegfilgrastim Biosimilars Market Overview
  • 25.2. Canada Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Pegfilgrastim Biosimilars Market

  • 26.1. South America Pegfilgrastim Biosimilars Market Overview
  • 26.2. South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Pegfilgrastim Biosimilars Market

  • 27.1. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Pegfilgrastim Biosimilars Market

  • 28.1. Middle East Pegfilgrastim Biosimilars Market Overview
  • 28.2. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Pegfilgrastim Biosimilars Market

  • 29.1. Africa Pegfilgrastim Biosimilars Market Overview
  • 29.2. Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Pegfilgrastim Biosimilars Market Competitive Landscape And Company Profiles

  • 30.1. Pegfilgrastim Biosimilars Market Competitive Landscape
  • 30.2. Pegfilgrastim Biosimilars Market Company Profiles
    • 30.2.1. Coherus BioSciences
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Sandoz
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Biocon/Mylan
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Intas Biopharmaceuticals Ltd
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Mundipharma GmbH
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Pegfilgrastim Biosimilars Market Other Major And Innovative Companies

  • 31.1. Dr. Reddy's Laboratories
  • 31.2. Pfizer Inc.
  • 31.3. Emcure Pharmaceuticals
  • 31.4. USV Private Limited
  • 31.5. Apotex Pty Ltd
  • 31.6. Kyowa Kirin Co. Ltd
  • 31.7. Qilu Pharmaceutical
  • 31.8. Gennova Biopharmaceuticals Limited
  • 31.9. Lupin Limited
  • 31.10. Coherus Biosciences Inc
  • 31.11. Fresenius Kabi
  • 31.12. Napp Pharmaceuticals
  • 31.13. Boicon
  • 31.14. Amega Biotech.
  • 31.15. Glenmark Pharmaceuticals Ltd

32. Global Pegfilgrastim Biosimilars Market Competitive Benchmarking

33. Global Pegfilgrastim Biosimilars Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market

35. Pegfilgrastim Biosimilars Market Future Outlook and Potential Analysis

  • 35.1 Pegfilgrastim Biosimilars Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Pegfilgrastim Biosimilars Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Pegfilgrastim Biosimilars Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제